Royal Bank Of Canada Cellectis S.A. Transaction History

Royal Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.72 - $2.12 $15 - $19	-9 Reduced 13.85%	56 $0
Q4 2022 Feb 14, 2023	BUY	$1.85 - $2.6 $16 - $23	9 Added 16.07%	65 $0
Q3 2022 Nov 14, 2022	SELL	$2.29 - $4.08 $119 - $212	-52 Reduced 48.15%	56 $0
Q2 2022 Aug 15, 2022	BUY	$2.39 - $4.93 $43 - $88	18 Added 20.0%	108 $0
Q1 2022 May 16, 2022	SELL	$3.45 - $8.77 $16,856 - $42,850	-4,886 Reduced 98.19%	90 $0
Q4 2021 Feb 14, 2022	SELL	$8.01 - $12.84 $70,768 - $113,441	-8,835 Reduced 63.97%	4,976 $41,000
Q3 2021 Nov 15, 2021	BUY	$11.94 - $16.09 $84,212 - $113,482	7,053 Added 104.37%	13,811 $175,000
Q2 2021 Aug 16, 2021	BUY	$14.36 - $20.93 $97,044 - $141,444	6,758 New	6,758 $105,000

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.